Making breakthrough medicines is hard.

Carl is the founding CEO of AbCellera. As an entrepreneurial scientist working at the interface of engineering, biology, and computation, his work is represented in over 90 peer-reviewed manuscripts and abstracts, more than 75 patent applications, and nine successful commercial products. Carl is the recipient of numerous awards, including EY Canada’s Entrepreneur of Year. Before leading AbCellera, Carl cofounded Precision Nanosystems, a global leader in technologies, solutions, and services for the development of non-viral delivery of genomic medicines, including mRNA vaccines and therapeutics. He is also an adjunct professor at the University of British Columbia and served on the Scientific Advisory Board of Fluidigm Corp. Carl received his PhD in Applied Physics/Biotechnology from Caltech and a BASc in Engineering Physics and Honors Mathematics from the University of British Columbia.

Véronique Lecault is Cofounder, Chief Technology Officer and member of the Board of Directors at AbCellera. She co-invented the high-throughput microfluidic platform that is a core part of AbCellera's antibody discovery technology. As Chief Technology Officer, Véronique is responsible for AbCellera’s technical operations, including process development, clinical manufacturing, and quality functions, as well as engineering, data science and infrastructure. Véronique previously served as AbCellera’s Chief Operating Officer from 2019 to 2025 and oversaw the company’s growth to 600+ team members.

‍

Véronique was named one of Canada’s Top 40 Under 40, is a uOttawa Alumna of the Year, a recipient of the UBC Faculty of Applied Science Dean’s Medal of Distinction, and the recipient of L’Oreal-UNESCO For Women in Science Mentorship Award. She holds a BASc in Chemical Engineering/Honours BSc Biochemistry (Biotechnology) dual degree from the University of Ottawa and a PhD in Chemical and Biological Engineering from the University of British Columbia.

Michael is a Killam Professor of Medical Genetics at the University of British Columbia, Founder and Senior Scientist at the Centre for Molecular Medicine and Therapeutics (CMMT), and a Canada Research Chair in Human Genetics and Molecular Medicine. Michael previously served as CSO and President of Global R&D at Teva and has founded a number of biotech companies including Aspreva, Neurovir, Xenon, 89bio, and Prilenia. He has authored over 900 publications and invited submissions and is the most cited author in the world for Huntington’s Disease and ABCA1. Michael holds a number of awards including the Order of Canada (2010), the Canada Gairdner Wightman Award (2011), and the Diamond Jubilee Medal (2012). He is recognized as one of the “100 Most Inspiring People” in pharma and was inducted into the Canadian Medical Hall of Fame. He was also recently named one of the 20th century’s “50 Canadians who have changed the world”. Michael has an MB, ChB MD and a PhD degree in Genetics from the University of Cape Town.

Mr. Montalbano is Principal of Tower Beach Capital Ltd. and serves on the boards of the Canada Pension Plan Investment Board, Aritzia Inc., and the Asia Pacific Foundation of Canada. His previous appointments include the former Vice Chair of RBC Wealth Management and CEO of RBC Global Asset Management (RBC GAM). When Mr. Montalbano retired as CEO of RBC GAM in 2015, it was among the largest 50 asset managers worldwide with $370 billion under management and offices in Canada, the United States, the United Kingdom, and Hong Kong.

‍

Mr. Montalbano holds a Chartered Financial Analyst designation and a Bachelor of Commerce, with Honours, from the University of British Columbia. He is a Leslie Wong Fellow of the UBC Portfolio Management Foundation and holds an Honorary Doctor of Letters from Emily Carr University of Art and Design.

Dr. Lo has developed new financial engineering tools and business models for drug and device development and healthcare delivery, statistical methods for incorporating patient preferences into the drug approval process, and machine-learning for predicting clinical trial outcomes. He is a cofounder and director of BridgeBio Pharma, a director of Atomwise and Roivant Sciences, a cofounder and chairman of QLS Advisors, and a member of the advisory boards of NCATS and the American Cancer Society’s BrightEdge Impact Fund. Dr. Lo is currently the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT's Computer Science and Artificial Intelligence Laboratory. Dr. Lo was named one of TIME’s “100 most influential people in the world.”

Andrew became AbCellera’s CFO in 2019 after spending nearly 4 years on the company’s Board of Directors from 2016. Prior to joining AbCellera, Andrew spent 10 years at STEMCELL Technologies where he held roles as the CFO and the Chief Commercial Officer. Before STEMCELL, Andrew spent 7 years at General Electric, ending by leading M&A/Business Development for GE Healthcare’s Europe, Middle East, and Africa business and GE Healthcare’s global Life Sciences business based in London. Andrew is an advisor to Aspect Biosystems and 5AM Venture Capital. He was formerly the Chairman of Precision Nanosystems and a Director at the National Board of Canadian Manufacturers and Exporters, the BC Tech Association, Life Sciences BC and Light Integra Inc. Andrew holds an MBA from INSEAD and a BASc in Engineering Physics from the University of British Columbia.

Tryn Stimart is a seasoned executive with over 20 years of experience in the biotech and pharmaceutical industries. His expertise spans corporate legal matters, M&A and financing, SEC and FDA regulatory processes, licensing, privacy, commercial and patent litigation, IP strategy and prosecution, and due diligence.

‍

Before joining AbCellera, Tryn was a partner at Gibbons P.C. in Manhattan. He represented leading biotech and pharma clients in private practice, including Gilead, Takeda, Gevo, Sunovion, Syngenta, and Adare Pharma. He also served as an Advisor to the Advanced Technology Program of the U.S. Department of Commerce.

‍

A former United States Naval Officer (Lieutenant Commander) with a decade of active and reserve service, Tryn brings a strategic and disciplined approach to leadership. He holds a JD (cum laude) from American University Washington College of Law, where he was a senior editor on the Law Review, an MSc in Chemistry from Old Dominion University, and dual BSc degrees in Biochemistry and Genetics & Cell Biology from the University of Minnesota.

‍

In his personal time, Tryn enjoys family, cooking, wine, outdoor activities, hockey, tennis, and relaxing on the beach.

Neil Aubuchon is the Chief Commercial Officer at AbCellera. He has over 23 years of commercial experience at multinational bio-pharmaceutical companies. He has held a wide array of positions both within markets and at the global level, including leading a 1,000+ person organization.

‍

Prior to joining AbCellera, Neil was the Global Marketing Lead for Amgen's General Medicine early portfolio, which included responsibility for developing the integrated strategy for Amgen's non-oncology therapeutic areas and leading commercial strategy for over 10 biologics, as well as several high profile corporate initiatives. Prior to Amgen, Neil was the Vice President of Global Marketing at Santen, a global ophthalmology-focused pharmaceutical company. Prior to Santen, Neil spent close to 17 years at Eli Lilly in various commercial roles of increasing responsibility. This included the Chief Marketing Officer in Australia, Chief Marketing Officer in Japan, Head of Strategy & Operations for Lilly Bio-Medicines Globally, and Vice President of Lilly Bio-Medicines in Japan.

‍

Neil holds a BA in Political Science from the University of Western Ontario and an MBA from the University of Toronto.

Murray is responsible for negotiating AbCellera’s research, partnership, and license agreements and is a key contributor to the development and execution of corporate strategy. He has over 12 years of experience in technology commercialization and early-stage venture development. Before joining AbCellera, Murray was a Business Development Manager at Harvard University’s Office of Technology Development. Prior to Harvard, he was a Senior Consultant at Lux Research in Boston, where he specialized in technology strategy, market and competitive analysis, and M&A and investor diligence. Murray completed a postdoctoral fellowship at Harvard’s School of Engineering and Applied Sciences, and has PhD, MSc, and BSc degrees in Physics from the University of British Columbia. He also earned a BA in Philosophy, Politics and Economics from Oxford University, where he studied as a Rhodes Scholar.

Adam Clarke leads the Discovery team with almost 15 years of industry experience in the generation, optimisation and pre-clinical development of biologics. As a protein engineer, Adam has pioneered techniques in the discovery and engineering of monoclonal antibodies against challenging targets. Prior to joining AbCellera, Adam was most recently Senior Director, Biologics Lead Antibody Discovery at Teva Pharmaceuticals. During his time at Teva, Adam led a team of scientists that consistently generated therapeutic antibodies that proceeded to first-in-human trials, several of which are currently in later stage clinical trials. Adam completed postgraduate training in experimental medicine, earning a PhD from the University of Sydney (Prof Tony Weiss lab). He is the holder of 15 patent families and 12 scientific publications.

Janet leads Talent Development at AbCellera, including the Talent Discovery, People Support, Learning & Development, and Internal Communications teams. It was a surprisingly seamless transition from higher education into industry about 2 years ago. Today, she is focused on developing systems to support high-performing teams, as the company grows. Before joining AbCellera, Janet was Managing Director of Student Development and Services at the University of British Columbia. Leading teams to support student learning and the University during the years punctuated with a focus on health and wellbeing, digital transformation, internationalization, and career development. Janet holds a EdD (Simon Fraser University), a Certificate in Public Leadership from the Harvard Kennedy School and is a certified executive coach (Royal Roads).

Geoff is AbCellera’s SVP, Development and oversees the advancement of AbCellera’s late-preclinical and early clinical development programs. He brings nearly 30 years of experience, with his first drug development success in 1996.

‍

Prior to joining AbCellera, Geoff was Chief Medical Officer at BioMarin Pharmaceutical, managing  several clinical development programs through late stage clinical trials, approval, and commercialization. Geoff’s industry career started at SmithKline Beecham, and includes progressive roles as VP at Novartis, successively responsible for clinical development, US Medical Affairs, and Global Project and Portfolio Management, SVP of Development at Mederex, and EVP R&D at Sangamo BioSciences, where he managed an active gene therapy portfolio.

‍

At Medarex, Geoff was responsible for the foundational clinical development of the breakthrough cancer immunotherapy checkpoint inhibitors Yervoy and Opdivo, which culminated in the 2009 acquisition of Medarex by Bristol-Myers Squibb and the award, in 2018, of the Nobel Prize for Medicine or Physiology related to these programs.

‍

Geoff graduated from the Otago University Medical School in New Zealand, with advanced training in Thoracic Medicine. He also has an MBA from Warwick University, UK. Geoff is a Fellow of the Royal Australasian College of Physicians.

Kathleen is a Co-founder and Vice President of Discovery at AbCellera. A co-inventor on several patents, Kathleen has been instrumental in developing custom single-cell assays and dramatically increasing the throughput of AbCellera’s core screening technology. An expert in cell biology and high-throughput screening, she has led the growth of the Discovery teams at AbCellera. Kathleen has a PhD in Experimental Medicine at the BC Cancer Research Centre and a BSc (Hons) in Biophysics from the University of British Columbia.

Sherie is Vice President of Research Partnerships at AbCellera, responsible for managing discovery programs from target to completion. Sherie has over 20 years of management experience in biotechnology, science outreach and other industries, and is an expert in immunology, cell biology, and single cell assays. She has been awarded several scholarships from the Natural Sciences and Engineering Research Council of Canada (NSERC) as well as the British Columbia Industrial Innovation Scholarship. Sherie has a PhD in Experimental Medicine from the University of British Columbia and a BSc in Biological Sciences from Simon Fraser University.

Anne is the Vice President of Business Development at AbCellera and serves on the Board of Directors of LifeSciences BC and Aequus Pharmaceuticals. Previously, Anne was a Co-Founder and Senior Partner of Northview Lifesciences, an entity which invests in and provides strategic advisory services to a number of life sciences companies. Anne also served as the Chief Operating Officer for Aequus Pharmaceuticals, a publicly listed Canadian specialty pharmaceutical company where she was responsible for developing and executing on the corporate strategy, including building out the commercial pipeline through the execution of various types of partnerships with multi-national organizations. Anne’s earlier experience includes roles of increasing responsibility in business and corporate development, including at Cardiome Pharma Corp. and Bayer HealthCare, where she was responsible for strategic planning and value analysis of internal R&D as well as the commercial success and business development of a portfolio of products within several key therapeutic areas.

‍

Anne holds a Bachelor of Science degree and Master of Health Administration degree from University of British Columbia and is a past winner of Business in Vancouver’s “Top 40 Under 40 Award”.

Tiffany joined AbCellera in 2020 and leads strategic communications. She brings more than 17 years of experience translating science and technology into content that stimulates, educates, and catalyzes change. She co-founded Centrifuge Media Lab in 2010, where she led strategy and brand development for biotech, life science, and tech clients across the globe. Tiffany was previously the Global Communications Lead for Accenture at Best Buy and has held senior roles in the STEMCELL Technologies Group of Companies. She is currently on the Board of Directors for the Spring for Kids Foundation and is the past President of the Vancouver Asian Canadian Theatre. Tiffany completed her BSc in Integrated Science from the University of British Columbia.

Tina is Vice President of facilities at AbCellera. She leads capital projects for AbCellera’s campus development as well as facilities operations, maintenance, logistics, lab operations, health and safety, and workplace experience. Tina has over 30 years of combined experience in health and safety and facilities operations including Director of Facilities and Occupational Health and Safety at QLT where she led all aspects of planning, construction, and operation of complex facilities to support the research, development, and manufacturing of pharmaceutical products. After leaving QLT Tina founded MTY Consulting Group in 2012, where she led design and construction for biotech, life science, and tech clients across the lower mainland. Tina has also held health and safety roles at the British Columbia Institute of Technology  and Stanley Pharmaceuticals. Tina holds a Master of Arts in Leadership from Royal Roads University and a Diploma in Technology, Occupational Health and Safety from BCIT. She was born, raised and continues to live with her family on the North Shore.

Paul is a senior leader of the Complex Membrane Protein Technologies team and heads AbCellera’s Boston location. Paul has over twenty years experience developing and using protein expression platform technologies to generate recombinant protein for drug discovery. Prior to joining AbCellera, Paul was the lead scientist involved in developing and commercializing a yeast expression platform at New England Biolabs. He moved to TetraGenetics Inc, which was acquired by AbCellera in 2020, to direct the development of a new protein expression platform specifically designed to produce complex membrane proteins for biologics discovery using the ciliated protist Tetrahymena thermophila. Paul received his undergraduate degree from the University of Sydney and his PhD from the University of Illinois, Urbana Champaign. He is a contributing author of 30 peer-reviewed scientific publications, reviews, and book chapters and is listed as an inventor on over 15 patents.

Jake is Vice President of Alliance Management at AbCellera. Jake has over 20 years of experience in the biopharmaceutical industry in roles spanning discovery, development and commercialization. Previously, he served as Senior Director of Alliance and Program Management at Halozyme. Prior to Halozyme, Jake was Co-Founder and Chief Operating Officer at Sirenas, a startup focused on applying computational approaches to the discovery of small molecules therapeutics from natural sources. Prior to Sirenas, he held roles of increasing responsibility in the medical affairs and commercial organizations at Genentech. Before Genentech, he served on clinical development teams spanning Phases I-IV at Chugai Pharma USA, Corixa Corporation, and ICON plc. Jake received his PharmD from the University of California, San Francisco and earned a BA in biology from Vanderbilt University.

Darren Berry is the Vice President of Quality at AbCellera. He is a seasoned senior leader with nearly 30 years of international biopharmaceutical industry experience, including management of facility start-ups, product launches, and commercial manufacturing operations. Prior to joining AbCellera, Darren was the Chief Quality Officer for Biocon Biologics, with direct responsibility for clinical and commercial cGMP manufacturing of biosimilars (generic biologics) for patients globally.  Darren also spent 15 years working for Genentech/Roche based in Basel, Switzerland, where he held a number of leadership roles in quality and operations with direct responsibility for cGMP manufacturing sites across Europe, Asia, and Brazil. Earlier in his career, Darren was based in Canada and the USA working with Contract Manufacturing Organizations (Lonza, DSM) supporting facility design/start-up projects, facility licensure, and quality operations oversight for both clinical and commercial product supply. Darren holds a Bachelor of Science in Biochemistry from the University of Manitoba and Master of Business Administration from Athabasca University.